LEVEMIR Drug Profile

Summary for Tradename: LEVEMIR

High Confidence Patents:	39
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for LEVEMIR
Recent Clinical Trials:	See clinical trials for LEVEMIR

See drug prices for LEVEMIR

Recent Clinical Trials for LEVEMIR

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Novo Nordisk A/S	Phase 1
Minneapolis Medical Research Foundation	N/A
Hennepin Healthcare Research Institute	N/A

See all LEVEMIR clinical trials

Pharmacology for LEVEMIR

Ingredient-type	Insulin
Established Pharmacologic Class	Insulin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for LEVEMIR Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for LEVEMIR Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,220,155	2026-07-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,357,616	2037-11-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,376,652	2037-02-24	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	11,097,063	2039-01-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	11,311,679	2039-06-25	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	4,973,318	2009-02-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for LEVEMIR Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,016,338	2036-12-20	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,241,117	2038-04-27	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,251,957	2032-06-01	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,265,291	2037-02-13	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,328,157	2037-02-03	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,398,781	2037-08-18	Patent claims search

International Patents for LEVEMIR

Country	Patent Number	Estimated Expiration
South Korea	960704925
Russian Federation	2254878
Australia	720484
Australia	2005298946
European Patent Office	1877119
Spain	2394556

Supplementary Protection Certificates for LEVEMIR

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
PA2004005	Lithuania		PRODUCT NAME: INSULIN DETEMIR; REGISTRATION NO/DATE: EU/1/04/278/001, EU/1/04/278/002, EU/1/04/278/003, EU/1/04/278/004, EU/1/04/278/005, EU/1/04/278/006, EU/1/04/278/007, EU/1/04/278/008, EU/1/04/278/00 20040601
04C0020	France		PRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: LI - 56370 20031110
SPC/GB99/045	United Kingdom		SPC/GB99/045: 20060829, EXPIRES: 20110828
2004/015	Ireland		PRODUCT NAME: INSULIN DETEMIR; NAT REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION NO/DATE: CH 56370 56371 56372 20031110; PAEDIATRIC INVESTIGATION PLAN: P/0172/2014
C300160	Netherlands		PRODUCT NAME: INSULINE DETEMIRUM; NAT. REGISTRATION NO/DATE: EU/1/04/278/001EU/1/04/278/002EU/1/04/278/003EU/1/04/278/005EU/1/04/278/004EU/1/04/278/006EU/1/04/278/007EU/1/04/278/008EU/1/04/278/009 2004010601; FIRST REGISTRATION: 563705637156372EU/1/04/278/001 T/M -/009 2003101110
99C0044	Belgium		PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615

Market Dynamics and Financial Trajectory for the Biologic Drug: LEVEMIR

Last updated: September 23, 2025

---

Introduction

LEVEMIR (insulin detemir) is a long-acting basal insulin analog developed by Novo Nordisk, designed to manage blood glucose levels in patients with diabetes mellitus. Since its approval in the early 2000s, LEVEMIR has established itself within the competitive landscape of insulin therapies. This report examines the evolving market dynamics and financial trajectory shaping LEVEMIR’s position within the global diabetes treatment market, influenced by regulatory, competitive, technological, and economic factors.

---

Market Overview and Growth Drivers

Global Diabetes Epidemic and Insulin Market Expansion

The rising prevalence of diabetes worldwide is a primary catalyst fueling the insulin market’s growth. According to the International Diabetes Federation (IDF), approximately 537 million adults suffered from diabetes in 2021, with projections exceeding 700 million by 2045 [1]. The surge in type 1 and type 2 diabetes cases directly expands the patient base for insulin therapies like LEVEMIR.

Shift Toward Basal Insulin Preference

Clinicians increasingly favor long-acting insulins for their stable pharmacokinetics and reduced hypoglycemia risk. LEVEMIR’s profile—offering a predictable 24-hour duration—aligns with this shift, supporting its sustained demand. Market research indicates that basal insulins capture over 60% of total insulin prescriptions (market share), emphasizing long-term growth prospects for LEVEMIR.

Innovations and Biosimilar Competition

While originator products like LEVEMIR maintain dominance, biosimilar entrants—such as biosimilar glargines and detemir variants—are intensifying price competition. The advent of biosimilars catalyzes downward pressure on prices and margins, impacting LEVEMIR’s revenue potential.

---

Regulatory and Patent Landscape

Patent Expirations and Generic Competition

Novo Nordisk’s patent exclusivity for LEVEMIR was primarily secured until the mid-2010s, with subsequent patent litigations and expirations opening the door for biosimilar competition. The expiration of manufacturing patents permits biosimilar development, which could erode LEVEMIR’s market share in key regions like the EU and the US.

Regulatory Approvals for Biosimilars

Biosimilar approvals depend on rigorous regulatory pathways. In Europe, the European Medicines Agency (EMA) has approved biosimilar insulin products, such as Abasaglar (biosimilar glargine). In the US, the FDA’s abbreviated pathway for biosimilars under the Biologics Price Competition and Innovation Act (BPCIA) has fostered an influx of alternatives. These decisions significantly influence LEVEMIR’s future revenues.

---

Competitive Landscape

Major Competitors

• Insulin Glargine Variants: LANTUS (insulin glargine) by Sanofi, with subsequent biosimilars like Basaglar and Semglea.
• Insulin Degludec: Tresiba, marketed by Novo Nordisk, offers an ultra-long-acting alternative with greater flexibility.
• Emergent Biosimilars: Multiple biosimilars of long-acting insulins are in development or marketed, intensifying the price competition.

Differentiation Strategies

To maintain relevance, Novo Nordisk emphasizes LEVEMIR’s unique attributes and formulates value-based pricing models. Educational campaigns spotlight its safety profile and once-daily dosing, targeting both clinicians and patients.

---

Technological Trends Impacting Financial Trajectory

Advancements in Insulin Delivery

Innovations such as continuous glucose monitoring (CGM) and insulin pumps are enhancing diabetes management but also promoting alternative delivery modes that could reduce dependence on traditional injections like LEVEMIR.

Personalized Medicine and Digital Health

Integration of digital tools allows tailored treatment regimens. Companies investing in such technologies may influence the demand dynamics for basal insulins.

Emerging Alternatives

Non-insulin therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, are gaining prominence, especially for type 2 diabetes. While not direct competitors, these agents influence overall market shares and prescribing behaviors.

---

Financial Trajectory Analysis

Revenue Trends

While precise annual revenue figures for LEVEMIR are proprietary, estimates suggest that the product’s sales have plateaued or experienced modest declines in mature markets due to biosimilar commoditization and competitive pressures. Nonetheless, LEVEMIR remains a significant revenue generator for Novo Nordisk, contributing substantively to its diabetes franchise.

Profitability and Pricing

Price erosion has been observed following biosimilar entries, with wholesale prices decreasing by single-digit percentages over recent years. Novo Nordisk mitigates margin erosion through operational efficiencies, differentiated branding, and expanding access programs.

Regional Variations

• United States: A mature market with intense biosimilar competition; profit margins under pressure.
• Europe: Regulatory approvals for biosimilars have increased competition; however, healthcare systems' pricing negotiations often secure favorable terms for originators.
• Emerging Markets: Faster adoption rates, driven by affordability and expanding healthcare infrastructure, sustain LEVEMIR’s financial outputs.

Forecasting

Industry analysts project moderate compound annual growth rates (CAGRs) for basal insulin sales, roughly 3-5%, over the next five years. LEVEMIR’s revenue trajectory hinges on biosimilar uptake, pricing strategy, and market expansion.

---

Strategic Considerations for Stakeholders

• Pricing Strategies: Maintaining competitive pricing, especially in regions with biosimilar competition.
• Portfolio Diversification: Integration of LEVEMIR within broader diabetes management solutions.
• Innovation Investment: Formulating next-generation insulin analogs or combination therapies.
• Market Expansion: Targeting emerging markets with growing diabetes prevalence.
• Patient Engagement: Leveraging digital tools to enhance adherence and outcomes.

---

Conclusion

The landscape for LEVEMIR reflects a complex interplay of rising global diabetes prevalence, technological advancements, regulatory decisions, and competitive pressures. While growth prospects remain favorable in emerging markets and niche regions, the product’s financial trajectory faces headwinds from biosimilar erosion and evolving treatment paradigms. Strategic adaptation—through pricing, innovation, and market expansion—will be pivotal for maintaining LEVEMIR’s value proposition within the global insulin market.

---

Key Takeaways

• The global surge in diabetes cases sustains demand for long-acting insulins like LEVEMIR.
• Patent expirations and biosimilar entries are key factors heightening price competition.
• Differentiation through safety profile, dosing convenience, and digital health integration remain vital.
• Emerging markets present growth opportunities, while saturated regions require strategic pricing.
• Innovation in insulin formulations and delivery methods could impact LEVEMIR’s long-term financial trajectory.

---

FAQs

1. How does LEVEMIR compare to other long-acting insulins in terms of market share?
LEVEMIR holds a significant segment of the long-acting insulin market, but it faces stiff competition from insulins like Tresiba (insulin degludec) and biosimilar glargines, which have gained market share through superior pharmacokinetic profiles and cost advantages.

2. What are the primary factors influencing LEVEMIR’s revenue shrinking or growth?
Key factors include biosimilar competition, pricing strategies, regional market dynamics, advances in insulin delivery systems, and the emergence of non-insulin therapies that modify treatment algorithms.

3. How significant is biosimilar competition for LEVEMIR?
Biosimilar insulins pose a substantial challenge by offering similar efficacy at lower prices, pressuring originator sales, and prompting pricing negotiations.

4. What regions offer the greatest growth prospects for LEVEMIR?
Emerging markets such as China, India, and Latin America are poised for growth due to increasing diabetes prevalence, expanding healthcare access, and regulatory reforms favoring biosimilar acceptance.

5. What strategic actions can Novo Nordisk take to prolong LEVEMIR’s market viability?
Investing in differentiating features, expanding access through affordability initiatives, integrating digital health tools, and pursuing pipeline innovations will be crucial to sustaining product relevance.

---

Sources
[1] International Diabetes Federation, IDF Diabetes Atlas, 2021.